Roivant Sciences Ltd.
ROIV
Peringkat dalam Saham
#978
Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company... Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs. The firm's development pipeline targets a broad spectrum of diseases, including various forms of solid tumors and oncologic malignancies, hematological disorders like sickle cell disease and warm autoimmune hemolytic anemia, as well as rare conditions such as hypophosphatasia. Additionally, Roivant is developing treatments for immunological and dermatological ailments, including psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, thyroid eye diseases, and sarcoidosis, alongside tackling infections like staph aureus bacteremia. Founded in 2014, its operations are based in London, United Kingdom.
Harga Saham
$33.73
Terakhir disinkronkan: 2026-07-31
Kapitalisasi Pasar
$24.37B
Perubahan (1 hari)
-2.28%
Perubahan (1 tahun)
90.15%
Negara
GB
Perdagangan Roivant Sciences Ltd. (ROIV)
Kategori
Healthcare
Rasio P/B untuk Roivant Sciences Ltd. (ROIV)
Rasio P/B per October 2026 TTM: 5.73
Menurut laporan keuangan dan harga saham terbaru dari Roivant Sciences Ltd., rasio P/B saat ini (TTM) adalah 5.73. Pada akhir 2024, rasio P/B perusahaan adalah 1.37.
Riwayat rasio P/B untuk Roivant Sciences Ltd. dari 2020 hingga 2026
Rasio P/B pada akhir setiap tahun
| Tahun | Rasio P/B | Mengubah |
|---|---|---|
| 2026 (TTM) | 5.73 | 267.12% |
| 2025 | 1.56 | 14.08% |
| 2024 | 1.37 | -69.88% |
| 2023 | 4.54 | 127.54% |
| 2022 | 2.00 | -46.40% |
| 2021 | 3.73 | 6.30% |
| 2020 | 3.50 | 0.00% |
Rasio P/B untuk perusahaan sejenis atau pesaing
| Perusahaan | Rasio P/B | Perbedaan Rasio P/B | Negara |
|---|---|---|---|
| 6.251 | 9.15% |
US
|
|
| 13.2547 | 131.44% |
US
|
|
| 4.208 | -26.52% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | 7.95% |
NL
|
